The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Targeted therapies have revolutionized the treatment for many patients with non-small cell
lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last …

Vietnam, a low–middle-income Southeast Asian country with a population of 96.5 million, is
the 15th most populous country in the world. 1 In 1986, the Vietnamese Government …

Lung cancer is a leading cause of death in both men and women globally. The recent
development of tumor molecular profiling has opened opportunities for targeted therapies for …

Purpose This study investigated the clinical utility of next‐generation sequencing (NGS) for
detection of genetic alterations and its implications on treatment of lung adenocarcinoma in …

Background Lung cancer is the leading cause of cancer death in both men and women.
Quebec has the highest lung cancer mortality out of all provinces in Canada, believed to be …

Simple Summary Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene
are the most common alterations in non-small cell lung cancer (NSCLC); they are generally …

Background: Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral
oncogene homolog (K-RAS) are the most common driver genes in patients with non-small …

Simple Summary Lung cancer is the leading cause of cancer-related death. While sex and
age impact outcomes in non-small cell lung cancer (NSCLC), it is not clearly understood …

Background: Biomarker testing has gradually become standard of care in precision
oncology to help physicians select optimal treatment for patients. Compared to single-gene …